Roche Holding AG Bearer Shares RO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RO is a good fit for your portfolio.
News
-
Roche Breast-Cancer Drug Gets Priority Review in the U.S.
-
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
-
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
-
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog
-
Roche's Inavolisib Breast Cancer Treatment Gets FDA Breakthrough Therapy Designation
-
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
-
U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx
-
Roche ramps up obesity-drug competition with early-stage trial results
Trading Information
- Previous Close Price
- CHF 250.20
- Day Range
- CHF 248.60–254.80
- 52-Week Range
- CHF 229.40–314.20
- Bid/Ask
- CHF 250.20 / CHF 259.80
- Market Cap
- CHF 201.54 Bil
- Volume/Avg
- 159,334 / 37,951
Key Statistics
- Price/Earnings (Normalized)
- 12.83
- Price/Sales
- 3.34
- Dividend Yield (Trailing)
- 3.82%
- Dividend Yield (Forward)
- 3.82%
- Total Yield
- 3.84%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 103,605
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.83 | 57.38 | 14.12 |
Price/Book Value | 6.84 | 7.81 | 34.13 |
Price/Sales | 3.34 | 5.16 | 5.04 |
Price/Cash Flow | 12.30 | 18.16 | 14.59 |
Price/Earnings
RO
MRK
ABBV
Financial Strength
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.99 | 0.68 | 0.72 |
Current Ratio | 1.35 | 1.25 | 0.94 |
Interest Coverage | 14.93 | 3.97 | 3.95 |
Quick Ratio
RO
MRK
ABBV
Profitability
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 17.03% | 5.22% | 14.14% |
Return on Equity (Normalized) | 53.42% | 13.56% | 172.29% |
Return on Invested Capital (Normalized) | 26.30% | 8.29% | 27.87% |
Return on Assets
RO
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Gycslyngf | Xzrq | $779.7 Bil | |
JNJ
| Johnson & Johnson | Rxkrjspv | Yyks | $347.6 Bil | |
MRK
| Merck & Co Inc | Dblwnxz | Zmnm | $319.4 Bil | |
ABBV
| AbbVie Inc | Hllrbry | Xgks | $284.7 Bil | |
AZN
| AstraZeneca PLC ADR | Gmyxnyzds | Jjb | $236.8 Bil | |
NVS
| Novartis AG ADR | Dqcdsybb | Tnwf | $210.4 Bil | |
RHHBY
| Roche Holding AG ADR | Crxgdsjyxx | Zbfj | $206.4 Bil | |
AMGN
| Amgen Inc | Wrvpzksk | Qxt | $164.1 Bil | |
PFE
| Pfizer Inc | Sfzdmzqk | Rnrc | $159.8 Bil | |
SNY
| Sanofi SA ADR | Blvtwjxrk | Lvnq | $121.5 Bil |